MC2309A1 - Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs - Google Patents

Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs

Info

Publication number
MC2309A1
MC2309A1 MC912309D MC2309D MC2309A1 MC 2309 A1 MC2309 A1 MC 2309A1 MC 912309 D MC912309 D MC 912309D MC 2309 D MC2309 D MC 2309D MC 2309 A1 MC2309 A1 MC 2309A1
Authority
MC
Monaco
Prior art keywords
carotene
vitamins
beta
treatment
vascular accidents
Prior art date
Application number
MC912309D
Other languages
English (en)
Inventor
Hennekens Charles
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of MC2309A1 publication Critical patent/MC2309A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
MC912309D 1990-10-01 1991-09-27 Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs MC2309A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59202490A 1990-10-01 1990-10-01

Publications (1)

Publication Number Publication Date
MC2309A1 true MC2309A1 (fr) 1993-09-27

Family

ID=24368959

Family Applications (1)

Application Number Title Priority Date Filing Date
MC912309D MC2309A1 (fr) 1990-10-01 1991-09-27 Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs

Country Status (12)

Country Link
US (1) US5871766A (fr)
EP (1) EP0551427A4 (fr)
JP (1) JPH06501695A (fr)
KR (1) KR19980703596A (fr)
AU (1) AU660630B2 (fr)
BG (1) BG97678A (fr)
BR (1) BR9106938A (fr)
CA (1) CA2093008A1 (fr)
HU (1) HUT64837A (fr)
MC (1) MC2309A1 (fr)
RU (1) RU2126679C1 (fr)
WO (1) WO1992005780A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61197774A (ja) * 1985-02-27 1986-09-02 Sanden Corp 冷媒圧縮機用バルブプレ−ト
CA2061477A1 (fr) * 1991-03-25 1992-09-26 Lawrence J. Daher Composition analgesique contenant du beta-carotene
EP0689427B1 (fr) * 1993-03-22 2002-06-12 Cognis Australia Pty Ltd Composes therapeutiques pouvant se disperser dans l'eau, comprenant un carotenoide
DE69424537T2 (de) * 1993-03-22 2001-11-15 Cognis Australien Pty.Ltd., Victoria Therapeutischer wirkstoff zur behandlung von melanomen
AU700689B2 (en) * 1993-03-22 1999-01-14 Betatene Pty Ltd Therapeutic agent for the treatment of melanomas
US20040180865A1 (en) * 1993-06-04 2004-09-16 Jeffry W. Kreamer Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
JP2001522229A (ja) * 1997-04-02 2001-11-13 ザ・ジヤクソン・ラボラトリー 抗酸化剤タンパク質2、遺伝子及びそれらの使用方法
JP2002513411A (ja) 1997-04-04 2002-05-08 ヘンケル コーポレーション 高いバイオアベイラビリティを有するルテインエステル
IL121112A (en) * 1997-06-19 2005-11-20 Lycored Natural Prod Ind Ltd Synergistic pharmaceutical or dietary compositionscomprising lycopene and vitamin e for preventing ldl oxidation
EP0996431B1 (fr) * 1997-06-19 2004-03-31 Lycored Natural Products Industries Ltd Compositions synergiques pour lycopene et vitamine e permettant la prevention d'oxydation de lipoproteine de faible densite (ldl)
US6914073B2 (en) 1999-03-18 2005-07-05 Bristol Myers Squibb Company Vitamin formulation for cardiovascular health
DE60007576D1 (de) * 1999-03-18 2004-02-12 Bristol Myers Squibb Co Vitamin Formulierung für kardiovaskuläre Gesundheit
US6805880B1 (en) * 1999-08-20 2004-10-19 Ferrosan A/S Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
US6582721B1 (en) 1999-09-17 2003-06-24 Alcon, Inc. Stable carotene-xanthophyll beadlet compositions and methods of use
US20030104090A1 (en) * 2000-05-05 2003-06-05 Levy Pedro E. Supplements containing annatto extracts and carotenoids and methods for using the same
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
EP1273297A1 (fr) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamine E pour le traitement de maladies dans lesquelles la liaison du facteur de transcription NF-KB et/ou AP-1 aux sites cibles du promoteur à un effet bénéfique (ex. SIDA, infarctus cardiaque)
GB2380481B (en) * 2001-08-22 2003-12-03 Cambridge Theranostics Ltd Means for treatment of atherosclerosis
RU2216738C2 (ru) * 2001-09-14 2003-11-20 Рагино Юлия Игоревна Способ оценки антиоксидантного потенциала липопротеинов низкой плотности
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
EP2392562B1 (fr) 2002-07-29 2018-03-07 Cardax Pharma, Inc. Analogues caroténoïdes structurels pour l'inhibition et la réduction de maladie
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US8088363B2 (en) 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
AT502435B1 (de) * 2002-11-19 2008-01-15 Oekopharm Forschungs Und Entwi Pharmazeutische zusammensetzung umfassend ein wasserstoffübertragendes coenzym und chlorophyll
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
EP1750723A1 (fr) 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Analogues ou derives de carotenoide pour inhiber et reduire l'inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US7351424B2 (en) * 2004-07-22 2008-04-01 Bio Lut S.A. De C.V. Enhanced purity trans-lutein-ester compositions and methods of making same
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
US20060111580A1 (en) * 2004-10-01 2006-05-25 Lockwood Samuel F Methods for the synthesis of chiral dihydroxy ketone intermediates useful for the chiral synthesis of carotenoids
US20070065487A1 (en) * 2005-09-21 2007-03-22 Bio Lut S.A. De C.V. Trans-lutein xantophyll ester of high purity and high bioavailability in micellar solution and a process for the preparation thereof
US20070135521A1 (en) * 2005-12-14 2007-06-14 Yamaha Hatsudoki Kabushiki Kaisha Agent for Preventing Metabolic Syndrome
US7282225B1 (en) 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
EP3016644A4 (fr) * 2013-07-03 2017-01-25 Barrie Tan Coq10 (ubiquinone, ubiquinol), vitamine a (acide rétinoïque, rétinol), vitamine e (tocotriénol, tocophérol) et procédés pour les utiliser

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853993A (en) * 1973-05-01 1974-12-10 Univ Virginia Process for increasing oxygen diffusivity and method for treating atherosclerosis
JPS6053031B2 (ja) * 1978-03-31 1985-11-22 武田薬品工業株式会社 スピロ化合物およびその製造方法
US4491574A (en) * 1983-03-02 1985-01-01 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Reduction of high dose aspirin toxicity by dietary vitamin A
DE3582439D1 (de) * 1984-01-28 1991-05-16 Roshdy Ismail Mittel zur behandlung von herzerkrankungen.
US5346488A (en) * 1985-04-08 1994-09-13 The General Hospital Corporation Laser-induced ablation of atherosclerotic plaque
EP0204987B1 (fr) * 1985-05-15 1991-11-21 Roshdy Dr. Ismail Médicament contenant la vitamine E pour améliorer les qualités du sang
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
JP2619491B2 (ja) * 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
CA2011651A1 (fr) * 1989-03-08 1990-09-08 Gerald Shklar Compose et methode pour induire la regression des tumeurs
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
EP0746202A4 (fr) * 1992-01-06 1997-06-25 Health Maintenance Programs Composition contenant un anti-oxydant pharmaceutiquement actif et son procede d'utilisation dans la prevention et le traitement d'une restenose apres angioplastie
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
US5328845A (en) * 1992-03-27 1994-07-12 Universal Foods Corporation Fungal negative microorganism capable of producing high levels of beta-carotene
IL104736A0 (en) * 1992-03-27 1993-06-10 Zeagen Inc Method for producing beta-carotene using a fungal mated culture
DE69327100T2 (de) * 1992-06-04 2000-04-13 Betatene Pty. Ltd., Cheltenham Gemisch mit hohem gehalt an cis beta-carotin
US5310554A (en) * 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
EP0689427B1 (fr) * 1993-03-22 2002-06-12 Cognis Australia Pty Ltd Composes therapeutiques pouvant se disperser dans l'eau, comprenant un carotenoide
US5607839A (en) * 1993-07-22 1997-03-04 Nippon Oil Company, Ltd. Bacteria belonging to new genus process for production of carotenoids using same
US5589468A (en) * 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients

Also Published As

Publication number Publication date
EP0551427A4 (en) 1993-09-22
BR9106938A (pt) 1993-09-28
BG97678A (en) 1994-03-31
HU9300950D0 (en) 1993-06-28
US5871766A (en) 1999-02-16
CA2093008A1 (fr) 1992-04-02
KR19980703596A (ko) 1998-12-05
WO1992005780A1 (fr) 1992-04-16
HUT64837A (en) 1994-03-28
EP0551427A1 (fr) 1993-07-21
JPH06501695A (ja) 1994-02-24
AU660630B2 (en) 1995-07-06
AU8862191A (en) 1992-04-28
RU2126679C1 (ru) 1999-02-27

Similar Documents

Publication Publication Date Title
MC2309A1 (fr) Traitement a base de beta-carotene et de vitamines pour inhiber les accidents vasculaires majeurs
IT1211692B (it) Dispositivo per l'incontinenza orinaria femminile
BE889327A (fr) Preparations pharmaceutiques a base de peroxydes et d'erythromycines pour le traitement topique de l'acne
FI891247A7 (fi) Kylpyvalmiste
IL90128A0 (en) Emulsion of pesticidal oil in water and process for its use
EP0273763A3 (en) Fluorine-containing polymers and oxygen-permeating articles composed of said polymers
GB8919896D0 (en) Concentrates of modifying agents in polymers
GB2223225B (en) Neutrophil-activating factor: its production and use in treatment
PL266284A1 (en) Specific in form of emulsion
EP0427781A4 (en) Ozonides of terpenes and their medical uses
PH23866A (en) Body lubricating and cleansing fluid
TR26234A (tr) KüKüRTLE HIDROKARBON AKINTILARIN KOSTIK ICERMEYE- CEK BICIMDE KüKüRT MUHTEVASININ AZALTILMASI
DE3367169D1 (en) Catalyst and its use in the production of methyl methacrylate
FR2548538B1 (fr) Production d'interferon humain et procede pour le dosage de l'aptitude du sang a produire de l'interferon
EG19540A (en) Medicament pour le traitement de la dermatite
GB8912373D0 (en) Medicament for various skin and ulcer disorders
EP0412641A3 (en) Use of vitamin d in retinopathy
FR2640287B1 (fr) Dispositif pour tresser les cheveux et les fils
EP0407788A3 (en) Use of retinoids for the treatment and prophylaxis of immune related diseases
FR2645564B3 (fr) Escalier de securite pour evacuer les immeubles en cas de danger
PL272720A1 (en) Bath liquid with gentle skin action
FR2632163B3 (fr) Sous-vetements pour femmes
FR2545719B1 (fr) Table-siege de massage et d'etirement
KR890000009U (ko) 이앙기의 식입 포오크와 식모침
KR870018104U (ko) 무동력 자동침전 및 역 세척장치